Abeona Therapeutics Inc. (0H7R.L)
0H7R.L Stock Price Chart
Explore Abeona Therapeutics Inc. interactive price chart. Choose custom timeframes to analyze 0H7R.L price movements and trends.
0H7R.L Company Profile
Discover essential business fundamentals and corporate details for Abeona Therapeutics Inc. (0H7R.L) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Medical - Pharmaceuticals
IPO Date
29 Jan 2018
Employees
136.00
CEO
Vishwas Seshadri
Description
Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening rare genetic diseases. Its lead program is EB-101, an autologous, gene-corrected cell therapy that is in Phase III clinical trial for recessive dystrophic epidermolysis bullosa. The company also develops ABO-102, an adeno-associated virus (AAV)-based gene therapy for Sanfilippo syndrome type A; ABO-201 to treat CLN3 disease; ABO-401 for the treatment of cystic fibrosis; and ABO-50X for the treatment of genetic eye disorders. In addition, it is developing AAV-based gene therapy through its AIM vector platform programs. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. was incorporated in 1974 and is headquartered in New York, New York.
0H7R.L Financial Timeline
Browse a chronological timeline of Abeona Therapeutics Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 13 May 2026
Upcoming earnings on 18 Mar 2026
Upcoming earnings on 12 Nov 2025
Upcoming earnings on 11 Aug 2025
Revenue estimate is $21.71M.
Earnings released on 15 May 2025
EPS came in at -$0.24 surpassing the estimated -$0.36 by +32.96%.
Earnings released on 20 Mar 2025
EPS came in at -$0.20 surpassing the estimated -$0.35 by +41.49%.
Earnings released on 14 Nov 2024
EPS came in at -$0.63 falling short of the estimated -$0.39 by -60.51%.
Earnings released on 12 Aug 2024
EPS came in at $0.14 surpassing the estimated -$0.34 by +142.28%.
Earnings released on 15 May 2024
EPS came in at -$1.16 falling short of the estimated -$0.51 by -125.21%.
Earnings released on 18 Mar 2024
EPS came in at -$0.65 falling short of the estimated -$0.47 by -38.13%.
Earnings released on 13 Nov 2023
EPS came in at -$0.48 surpassing the estimated -$0.53 by +10.51%.
Earnings released on 8 Aug 2023
EPS came in at -$0.92 falling short of the estimated -$0.67 by -37.27%, while revenue for the quarter reached $3.50M.
Earnings released on 24 May 2023
EPS came in at -$0.54 surpassing the estimated -$0.61 by +11.68%.
Earnings released on 29 Mar 2023
EPS came in at -$0.06 surpassing the estimated -$0.75 by +91.53%, while revenue for the quarter reached $68.00K, missing expectations by -93.20%.
Earnings released on 30 Sept 2022
EPS came in at -$1.48 surpassing the estimated -$1.75 by +15.44%.
Stock split effective on 11 Jul 2022
Shares were split 1:25, changing the number of shares outstanding and the price per share accordingly.
Stock split effective on 5 Jul 2022
Shares were split 1:25, changing the number of shares outstanding and the price per share accordingly.
Earnings released on 30 Jun 2022
EPS came in at -$1.43 surpassing the estimated -$1.88 by +23.81%, while revenue for the quarter reached $1.00M.
Earnings released on 31 Mar 2022
EPS came in at -$3.59 falling short of the estimated -$2.38 by -51.06%, while revenue for the quarter reached $346.00K.
Dividend declared on 15 Mar 2022
A dividend of $0.01 per share was announced, adjusted to $0.29.
Earnings released on 31 Dec 2021
EPS came in at -$11.15 falling short of the estimated -$3.67 by -204.00%, while revenue for the quarter reached $3.00M.
Earnings released on 30 Sept 2021
EPS came in at -$1.80.
Earnings released on 30 Jun 2021
EPS came in at -$3.94.
Earnings released on 31 Mar 2021
EPS came in at -$4.25.
Earnings released on 31 Dec 2020
EPS came in at -$4.26, while revenue for the quarter reached $3.00M.
Earnings released on 30 Sept 2020
EPS came in at -$1.95, while revenue for the quarter reached $7.00M.
0H7R.L Stock Performance
Access detailed 0H7R.L performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.